Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials

DSpace/Manakin Repository

Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials

Citable link to this page

 

 
Title: Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
Author: Zhao, Ying Jiao; Lin, Liang; Teng, Monica; Khoo, Ai Leng; Soh, Lay Beng; Furukawa, Toshiaki A.; Baldessarini, Ross J.; Lim, Boon Peng; Sim, Kang

Note: Order does not necessarily reflect citation order of authors.

Citation: Zhao, Ying Jiao, Liang Lin, Monica Teng, Ai Leng Khoo, Lay Beng Soh, Toshiaki A. Furukawa, Ross J. Baldessarini, Boon Peng Lim, and Kang Sim. 2016. “Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials.” BJPsych open 2 (1): 59-66. doi:10.1192/bjpo.bp.115.002576. http://dx.doi.org/10.1192/bjpo.bp.115.002576.
Full Text & Related Files:
Abstract: Background: For treatment of patients diagnosed with schizophrenia, comparative long-term effectiveness of antipsychotic drugs to reduce relapses when minimising adverse effects is of clinical interest, hence prompting this review. Aims To evaluate the comparative long-term effectiveness of antipsychotic drugs. Method We systematically searched electronic databases for reports of randomised controlled trials (RCTs) of antipsychotic monotherapy aimed at reducing relapse risks in schizophrenia. We conducted network meta-analysis of 18 antipsychotics and placebo. Results: Studies of 10 177 patients in 56 reports were included; treatment duration averaged 48 weeks (range 4–156). Olanzapine was significantly more effective than chlorpromazine (odds ratio (OR) 0.35, 95% CI 0.14–0.88) or haloperidol (OR=0.50, 95% CI 0.30–0.82); and fluphenazine decanoate was more effective than chlorpromazine (OR=0.31, 95% CI 0.11–0.88) in relapse reduction. Fluphenazine decanoate, haloperidol, haloperidol decanoate and trifluoperazine produced more extrapyramidal adverse effects than olanzapine or quetiapine; and olanzapine was associated with more weight gain than other agents. Conclusions: Except for apparent superiority of olanzapine and fluphenazine decanoate over chlorpromazine, most agents showed intermediate efficacy for relapse prevention and differences among them were minor. Typical antipsychotics yielded adverse neurological effects, and olanzapine was associated with weight gain. The findings may contribute to evidence-based treatment selection for patients with chronic psychotic disorders. Declaration of interest R.J.B. received grants from the Bruce J. Anderson Foundation and the McLean Private Donors Psychopharmacology Research Fund. Copyright and usage © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.
Published Version: doi:10.1192/bjpo.bp.115.002576
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995551/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29408187
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters